Aadi Bioscience Future Growth
Future criteria checks 2/6
Aadi Bioscience is forecast to grow earnings and revenue by 56.1% and 38.8% per annum respectively while EPS is expected to grow by 55.9% per annum.
Key information
56.1%
Earnings growth rate
55.9%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 38.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 43 | -26 | -52 | N/A | 3 |
| 12/31/2025 | 28 | -29 | -56 | N/A | 4 |
| 12/31/2024 | 26 | -52 | -49 | N/A | 2 |
| 9/30/2024 | 25 | -62 | -56 | -54 | N/A |
| 6/30/2024 | 24 | -65 | -54 | -50 | N/A |
| 3/31/2024 | 24 | -69 | -61 | -58 | N/A |
| 12/31/2023 | 24 | -66 | -64 | -60 | N/A |
| 9/30/2023 | 23 | -63 | -65 | -61 | N/A |
| 6/30/2023 | 22 | -62 | -60 | -58 | N/A |
| 3/31/2023 | 19 | -62 | -53 | -52 | N/A |
| 12/31/2022 | 15 | -61 | -50 | -50 | N/A |
| 9/30/2022 | 11 | -63 | -51 | -51 | N/A |
| 6/30/2022 | 7 | -136 | -60 | -60 | N/A |
| 3/31/2022 | 3 | -119 | -52 | -52 | N/A |
| 12/31/2021 | 1 | -111 | -22 | -22 | N/A |
| 9/30/2021 | 14 | -87 | -13 | -13 | N/A |
| 6/30/2021 | 15 | -2 | 1 | 1 | N/A |
| 3/31/2021 | 15 | -6 | 2 | 2 | N/A |
| 12/31/2020 | 15 | -4 | -13 | -13 | N/A |
| 12/31/2019 | 1 | -13 | -8 | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3350 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 3350 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 3350 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 3350's revenue (38.8% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 3350's revenue (38.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 3350's Return on Equity is forecast to be high in 3 years time